The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

ERIN DUNBAR: Plural neurofibromas are the signature abnormal tumor growth found in neurofibromatosis type 1, which is a heritable or familial or genetic condition, and plexiform neurofibromas are ...

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...

Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 ...

The goal of treatment for plexiform neurofibromas when they are diagnosed is to help that individual patient with how they're affecting them. So for many of those patients, those plexiform ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

Plexiform neurofibromas (PNs) are benign tumors that develop in individuals with NF1. These slow-growing, painless, and ...

Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Ph ...

This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1, a genetic disorder that causes noncancerous tumors to grow on nerves ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

Credit: Getty Images The FDA is expected to decide on treatments for Parkinson disease, PTSD and NF1-associated plexiform neurofibromas, in addition to 2 new vaccines. The FDA is reviewing the ...